Daily Newsletter

10 August 2023

Daily Newsletter

10 August 2023

FDA grants approval for Boston Scientific’s cryoablation system

The new POLARx FIT catheter can be adjusted to fit the anatomy of patients during the procedure.

Vishnu Priyan August 09 2023

The US Food and Drug Administration (FDA) has granted approval for Boston Scientific’s cryoablation system, dubbed POLARx.

The system is intended for treating paroxysmal atrial fibrillation (AF) patients.

It features the POLARx FIT cryoablation balloon catheter built with the ability to enable two balloon sizes, 28mm and 31mm, in a single catheter.

A minimally invasive procedure, cryoablation facilitates AF treatment by delivering cryotherapy to the pulmonary vein through a balloon catheter.

This approach freezes the affected tissue to create scarring, thereby hindering irregular electrical signals.

The new POLARx FIT catheter can be adjusted to fit the anatomy of patients during the procedure and helps address various limitations.

According to findings from the FROZEN-AF IDE clinical trial, POLARx was found to be safe and effective in treating paroxysmal AF patients. 

At 12 months, the primary event-free rate was reported to be 96%, without any cases of persistent phrenic nerve palsy or oesophagal fistulas and moderate or severe pulmonary vein stenosis. 

Boston Scientific electrophysiology president Nick Spadea-Anello said: “The US approval of the POLARx cryoablation system, which has been used in more than 25,000 patients worldwide to date, marks an exciting advancement for the treatment of AF and a new era of cryoablation capabilities.

“By prioritising procedural flexibility and individualised care, this offering transforms a key therapy in the electrophysiology space, addresses the unmet needs of physicians and affirms our commitment to making meaningful innovations to established technologies.”

The company recently posted GAAP net income attributable to its common stockholders of $261m in Q2 2023.

Healthcare companies are hesitant to invest in the metaverse

The COVID-19 pandemic pushed the healthcare industry to rapid digitalization. Increased use of telehealth, telepresence systems, remote diagnostics, predictive AI, and wearable technology is changing how healthcare is delivered and improving patient outcomes. Emerging technologies such as AR and VR are becoming increasingly routine for professional training, surgical assistance, and treatment of psychological and neurological disorders. In the pharma and medical devices industries, AR, VR, and AI are rapidly accelerating drug discovery and manufacturing and generating supply chain efficiencies. New digital opportunities will look to build upon disruptive technologies. However, affordability is a limiting factor to widespread adoption. Per GlobalData estimates, the metaverse market is expected to grow at a CAGR of more than 33% between 2023 and 2030. Although metaverse technologies could reinvent healthcare approaches and bring new experiences to healthcare providers and patients, adoption is still at an early stage. There are currently few use cases in the healthcare industry. The metaverse needs to overcome major challenges for healthcare, including regulation and data privacy concerns. Evidence of proven use cases and participation by a critical mass of users are imperative to drive a shift in metaverse investment.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close